Hobbs Named CEO Of Delcath Systems
July 6, 2009 (FinancialWire) — Medical technology firm Delcath Systems, Inc. (NASDAQ: DCTH) has named Eamonn P. Hobbs as its president and CEO. Hobbs, who has been a member of the company board since October 2008, succeeds Richard Taney, who has led the company since December 2006 and will continue to serve on the Delcath board.
From 1988 until earlier this year, Hobbs was president and CEO of AngioDynamics, Inc. (NASDAQ: ANGO), a firm he co-founded. In 2004, AngioDynamics was spun off from E-Z-EM, Inc., a healthcare company focused on diagnostic technologies, where Hobbs served as senior VP since 1988.
New York-based Delcath Systems is a medical device company specializing in cancer treatment. The company is testing a proprietary, patented drug delivery system for the treatment of liver cancers.
Delcath’s novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient’s bloodstream. The company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan.
FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.
Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
